Cannabis and Epilepsy: How CBD Became an FDA-Approved Treatment

The Short Answer

Cannabis and epilepsy have one of the more clinically-established relationships in the cannabis-medicine space. Epidiolex, a purified plant-derived CBD pharmaceutical, was approved by the FDA in 2018 for the treatment of specific rare, severe childhood-onset epilepsy syndromes (Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex). This is the first, and as of early 2026, one of the only — FDA-approved medications derived directly from the cannabis plant.

What Epidiolex Is

Epidiolex is a purified CBD solution manufactured under pharmaceutical standards. It is:

• Plant-derived from hemp.
• Highly purified (over 98 percent CBD).
• Prescribed by neurologists for the approved indications.
• Covered by insurance for the approved indications.
• Tested in large-scale randomized controlled trials that demonstrated seizure-frequency reduction.

Which Epilepsy Syndromes It Treats

The three approved indications:

Dravet syndrome. A rare, severe, treatment-resistant childhood epilepsy with multiple seizure types and significant developmental impact.

Lennox-Gastaut syndrome. Another severe childhood-onset epilepsy with multiple seizure types and often significant cognitive involvement.

Tuberous sclerosis complex (TSC). A genetic condition that can cause seizures (along with other manifestations).

Epidiolex is approved for patients one year and older with these conditions. It is not approved for general epilepsy, adult-onset seizure disorders, or other neurological conditions.

The Research Behind the Approval

Epidiolex approval followed multiple randomized, placebo-controlled trials showing statistically significant reductions in seizure frequency. Key findings:

• Reduction in seizure frequency across all three indications.
• Some patients saw dramatic responses; others had minimal response.
• Side effects include drowsiness, decreased appetite, diarrhea, liver-enzyme elevations in some patients (requiring monitoring).
• Drug interactions with other seizure medications, particularly clobazam, require careful dose management.

Why This Matters for Other Conditions

Epidiolex's approval:

• Validates the clinical-research pathway for cannabis-derived medications.
• Demonstrates that rigorous trials are possible despite federal Schedule I status.
• Provides a model for other cannabis-derived pharmaceuticals.
• Doesn't translate to general endorsement of non-pharmaceutical CBD for other conditions, the approval is for specific indications, not CBD in general.

CBD for Non-Approved Indications

Consumer CBD products are sometimes marketed with seizure-related claims. Important distinctions:

• Epidiolex is a pharmaceutical dosed under medical supervision at levels typically 5 to 25 mg/kg/day.
• Consumer CBD products are sold at much lower doses with no pharmaceutical QC.
• Non-Epidiolex CBD for the approved epilepsy indications is not recommended substitution; patients should use the approved medication under neurologist supervision.

Cannabis (Not Just CBD) for Epilepsy

THC-containing cannabis products have been studied for some seizure conditions with less consistent results. Some parents of children with severe epilepsy have pursued whole-plant or high-CBD cannabis under state medical programs before Epidiolex approval. The clinical picture is complex and individualized.

Where to Go Next

Related reading: medical cannabis 101, cbd oil benefits, and full-spectrum vs broad-spectrum vs isolate.

---

*This article is consumer education for adults 21+. Nothing here is medical, legal, or financial advice. Cannabis laws vary by state, always verify your state's current rules and, for health questions, consult a licensed clinician. For regulated New York retail, verify licensing via the OCM QR-code system at cannabis.ny.gov.*